Medication: Farxiga (dapagliflozin)

Part 1:
Medication paper outline.
Submit a complete, organized, detailed outline of your medication paper.

The thesis is concise and clearly articulated in the beginning. Subtopics are pertinent and highly relevant to the main body paragraphs

Part 2:
Medication paper : Farxiga (dapagliflozin)

Your paper must be a minimum of 6 pages, not including your title or reference pages. You should include at least five recent references (published within the last five years), and the paper must be presented in APA format.

The paper must include the following content information:

Manufacturing company
Brand name
First in class, or not first in class
Common side effects profile
Known contradictions
Make sure you explain the special considerations that your chosen drug has on the unique populations/client  (example: Geriatrics, patients with renal dysfunction, pregnancy). Special considerations should include absorption, clearance/elimination, distribution, metabolism half-life, loading dose, route of drug administration, and steady state

Title page

Reference page with a minimum of 5 references and appropriately used in-text citations for each
Visuals: tables, figures, graphs, charts, images, or any other non-text content. (if applicable)

Farxiga (dapagliflozin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Dapagliflozin is a sodium-glucose co-transporter 2 inhibitor, decreases plasma glucose levels by suppressing renal glucose reabsorption and increasing urinary glucose excretion (Ptaszynska & et al. 2015). The FDA approved Farxiga on January 8, 2014. The recommended starting dose of FARXIGA is 5 mg once daily, taken in the morning, with or without food. In patients tolerating FARXIGA 5 mg once daily who require additional glycemic control, the dose can be increased to 10 mg once daily.

please provide your feedback after reading